DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer. Dr. Laxman will lead sales and support, commercial strategy and operations, and marketing as BioSkryb continues to scale its global presence.

DURHAM，N.C.-（BUSINESS WIRE）-BioSkryb Genomics是一家通过实现从发现到诊断的细胞生态系统最完整的多组学视图来转换单细胞分析的公司，已任命Ram Laxman博士为首席商业官。Laxman博士将领导销售和支持，商业战略和运营以及营销，因为BioSkryb将继续扩大其全球影响力。

He brings strong executive leadership experience and an extensive track record of building and scaling businesses at companies like 10x Genomics, Pacific Biosciences, and Illumina..

他为10x Genomics，Pacific Biosciences和Illumina等公司带来了强大的行政领导经验和丰富的建筑和规模化业务记录。。

Dr. Laxman joins BioSkryb from 10x Genomics, where he served as the President and General Manager, APAC. As the company’s first hire in APAC, he was instrumental in building 10x Genomics’ presence in the region. He established the Asian operational headquarters in Singapore, oversaw all aspects of the commercial business, managed a team of approximately 100 colleagues across offices in Singapore, Shanghai, and Tokyo, and scaled its APAC revenue to over $100 million..

Laxman博士加入10x Genomics的BioSkryb，担任APAC的总裁兼总经理。作为该公司在APAC的第一份雇用，他在该地区建立了10x Genomics的业务。他在新加坡设立了亚洲运营总部，负责商业业务的各个方面，管理着新加坡，上海和东京各地约100名同事组成的团队，并将APAC的收入扩大到1亿多美元。。

“BioSkryb has developed a best-in-class DNA-informed single-cell multiomics portfolio that can provide a deeper understanding of the cell-to-cell genomic variability that is critical for the development of more precise and effective treatments for diseases like cancer,” said Dr. Ram Laxman, CCO, BioSkryb Genomics.

“BioSkryb开发了一流的DNA信息单细胞多组学组合，可以更深入地了解细胞间基因组变异性，这对于开发更精确有效的癌症等疾病治疗方法至关重要，”Ram Laxman博士，CCO，BioSkryb Genomics。

“Having been at the forefront of genomics and single-cell sequencing, I believe BioSkryb’s technology offers the next big leap in advancing single-cell genomics. Integrated multiomics is the future, and BioSkryb’s technology will play a foundational role in the next decades in discoveries and diagnostics in the broader genomics market.

“一直处于基因组学和单细胞测序的前沿，我相信BioSkryb的技术为推进单细胞基因组学提供了下一个大跃进。整合多组学是未来，BioSkryb的技术将在未来几十年发挥基础作用。在更广泛的基因组学市场中发现和诊断。

I’m looking forward to scaling BioSkryb’s presence across the globe and driving our commercial pipeline to bring our technology to new users.”.

我期待扩大BioSkryb在全球的影响力，推动我们的商业渠道，将我们的技术带入新用户“。

Before 10x Genomics, Dr. Laxman was part of the very early commercial teams at Illumina and Pacific Biosciences. Dr. Laxman holds a Ph.D. in molecular biology and served as a postdoctoral fellow with the eminent Professor Daniel Koshland at the University of California, Berkeley.

在10x Genomics之前，Laxman博士是Illumina和Pacific Biosciences早期商业团队的一部分。Laxman博士拥有分子生物学博士学位，并与加州大学伯克利分校的杰出教授Daniel Koshland一起担任博士后研究员。

“We are excited to welcome Ram to our leadership team and know that his deep expertise in establishing and growing a solid presence for some of the most successful companies in the genomics space will allow us to exponentially increase our international footprint,” said Suresh Pisharody, CEO, BioSkryb.

“我们很高兴欢迎Ram加入我们的领导团队，并知道他在基因组学领域为一些最成功的公司建立和发展坚实存在的深刻专业知识将使我们能够以指数方式增加我们的国际足迹，”Suresh Pisharody说，BioSkryb首席执行官。

“This year, BioSkryb has experienced a strong growth surge in North America where our focus has been, and with Ram on board, we are poised to drive significant growth for the company and expand the footprint of our industry leading single-cell products globally in the years to come.”.

“今年，BioSkryb在我们关注的北美地区经历了强劲的增长，并且随着Ram的出现，我们有望推动该公司的大幅增长，并扩大我们行业领先的单细胞产品的足迹。未来几年全球“。

Dr. Laxman’s predecessor, Reagan Tully, has been appointed Chief Business Officer of the organization, leading corporate, business, and market development functions, focused on expansion and adoption of the technology through key partnerships and collaborations across the industry.

Laxman博士的前任里根·图利（Reagan Tully）已被任命为该组织的首席商务官，领导公司，业务和市场发展职能，专注于通过行业间的关键合作伙伴关系和合作来扩展和采用该技术。

These appointments reflect BioSkryb’s continued momentum in advancing single-cell analysis, including the launch of ResolveOME™, a revolutionary multiomic solution, and the first-of-its-kind BaseJumper™ platform for multimodal bioinformatics analysis. Additionally, BioSkryb recently announced a significant distribution agreement to expand its services offering across Singapore and Southeast Asia..

这些任命反映了BioSkryb在推进单细胞分析方面的持续势头，包括推出ResolveOME™,一个革命性的多组学解决方案，以及第一个同类的BaseJumper™多模式生物信息学分析平台。此外，BioSkryb最近宣布了一项重要的分销协议，以扩大其在新加坡和东南亚的服务。。

To learn more about BioSkryb, please visit https://www.bioskryb.com/.

要了解更多关于BioSkryb的信息，请访问https://www.bioskryb.com/.

About BioSkryb Genomics

关于BioSkryb基因组学

BioSkryb Genomics is a rapidly growing organization that is transforming single cell molecular discovery and analysis. Through its single cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome, and proteome within a single cell to better understand the drivers, mechanisms, and management of complex disease.

BioSkryb Genomics是一个快速发展的组织，正在改变单细胞分子的发现和分析。通过其单细胞全基因组和全转录组扩增工具，科学家和临床医生可以在单个细胞内获得前所未有的基因组，转录组和蛋白质组视图，以更好地了解复杂疾病的驱动因素，机制和管理。

The company is headquartered in Durham, North Carolina. For more information, visit bioskryb.com..

该公司总部设在北卡罗来纳州达勒姆。欲了解更多信息，请访问bioskryb.com。。